Related Experiment Videos
Insulin aspart: a new rapid-acting insulin analog
S M Setter1, C F Corbett, R K Campbell
1College of Pharmacy, Washington State University, Spokane 99201-3899, USA. setters@wsu.edu
The Annals of Pharmacotherapy
|January 6, 2001
Summary
Insulin aspart is a rapid-acting insulin analog that effectively controls blood glucose after meals. This mealtime insulin offers a convenient option for diabetes management, improving quality of life.
Area of Science:
- Pharmacology and Therapeutics
- Endocrinology
- Diabetes Mellitus Management
Background:
- Insulin aspart is a rapid-acting insulin analog developed for diabetes mellitus treatment.
- It is produced via recombinant technology, modifying the B chain of human insulin.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, and therapeutic use of insulin aspart.
- To summarize clinical trial data on the efficacy and safety of insulin aspart in type 1 and type 2 diabetes.
Main Methods:
- A comprehensive literature search of MEDLINE (1985-May 2000) and other sources.
- Inclusion of published articles, abstracts, and unpublished data where available.
- Review of all identified published clinical studies on insulin aspart.
Main Results:
- Insulin aspart dissociates rapidly into active monomers/dimers after subcutaneous injection.
- When taken before meals, it effectively controls postprandial glucose, comparable to regular human insulin.
- It provides faster peak action and shorter duration compared to regular human insulin.
Conclusions:
- Insulin aspart is a practical premeal insulin for patients needing mealtime insulin therapy.
- Its pharmacokinetic profile ensures effective postprandial glucose control and enhances patient quality of life.